DexCom (NASDAQ:DXCM) Shares Unloaded Rep. Kevin Hern

Representative Kevin Hern (R-Oklahoma) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $50,001 and $100,000 in DexCom stock on December 31st. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST > BROKERAGE INVESTMENT ACCOUNT” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Intel (NASDAQ:INTC) on 12/31/2024.
• Sold $250,001 – $500,000 in shares of Devon Energy (NYSE:DVN) on 12/31/2024.
• Sold $15,001 – $50,000 in shares of Estée Lauder Companies (NYSE:EL) on 12/31/2024.
• Sold $100,001 – $250,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/31/2024.
• Sold $50,001 – $100,000 in shares of AGCO (NYSE:AGCO) on 12/31/2024.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 12/12/2024.
• Purchased $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 12/10/2024.
• Purchased $100,001 – $250,000 in shares of McDonald’s (NYSE:MCD) on 10/29/2024.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $84.84 on Friday. The company has a market capitalization of $33.14 billion, a PE ratio of 50.80, a PEG ratio of 2.00 and a beta of 1.12. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock’s 50 day moving average price is $77.89 and its 200-day moving average price is $78.41. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Analyst Ratings Changes

A number of analysts recently commented on the company. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $86.00 to $104.00 in a report on Thursday. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. JPMorgan Chase & Co. raised their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Raymond James dropped their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Finally, Canaccord Genuity Group increased their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $99.29.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Ballentine Partners LLC purchased a new position in DexCom during the fourth quarter valued at approximately $215,000. MassMutual Private Wealth & Trust FSB boosted its holdings in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares during the period. Bridgewater Advisors Inc. grew its position in shares of DexCom by 3.4% during the 4th quarter. Bridgewater Advisors Inc. now owns 13,017 shares of the medical device company’s stock valued at $1,031,000 after purchasing an additional 433 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of DexCom by 82.4% in the fourth quarter. UMB Bank n.a. now owns 1,678 shares of the medical device company’s stock worth $130,000 after purchasing an additional 758 shares during the period. Finally, Sax Wealth Advisors LLC boosted its stake in DexCom by 135.8% during the fourth quarter. Sax Wealth Advisors LLC now owns 14,284 shares of the medical device company’s stock valued at $1,111,000 after buying an additional 8,226 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.30% of the stock is owned by company insiders.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2025. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2024 election. Before running for Congress, Hern was a McDonald’s franchisee and served on the McDonald’s National Leadership Team. Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.